Your browser doesn't support javascript.
loading
Identifying patients with malignant spinal cord compression (MSCC) near end of life who can benefit from palliative radiotherapy.
Rades, Dirk; Segedin, Barbara; Schild, Steven E; Lomidze, Darejan; Veninga, Theo; Cacicedo, Jon.
Afiliación
  • Rades D; Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. dirk.rades@uksh.de.
  • Segedin B; Department of Radiotherapy, Institute of Oncology Ljubljana and University of Ljubljana, Ljubljana, Slovenia.
  • Schild SE; Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ, USA.
  • Lomidze D; Radiation Oncology Department, Ingorokva High Medical Technology University Clinic and Tbilisi State Medical Univiversity, Tbilisi, Georgia.
  • Veninga T; Department of Radiotherapy, Dr. Bernard Verbeeten Institute, Tilburg, The Netherlands.
  • Cacicedo J; Department of Radiation Oncology, Biocruces Bizkaia Health Research Institute and Cruces University Hospital, Barakaldo, Vizcaya, Spain.
Radiat Oncol ; 17(1): 143, 2022 Aug 17.
Article en En | MEDLINE | ID: mdl-35978340
ABSTRACT

BACKGROUND:

A previous score predicted death ≤ 2 months following radiotherapy for MSCC. For patients with a high probability of early death, best supportive care was recommended. However, some of these patients may benefit from radiotherapy regarding preservation or improvement of motor function. To identify these patients, an additional score was developed.

METHODS:

Pre-treatment factors plus radiotherapy regimen were retrospectively evaluated for successful treatment (improved motor function or remaining ambulatory without aid) and post-treatment ambulatory status in 545 patients who died ≤ 2 months. Factors included age, interval from tumor diagnosis until MSCC, visceral metastases, further bone metastases, primary tumor type, sex, time developing motor deficits, pre-treatment ambulatory status, and number of affected vertebrae. Factors significant on both multivariable analyses were included in the score (worse outcomes 0 points, better outcomes 1 point).

RESULTS:

On multivariable analyses, myeloma/lymphoma, time developing motor deficits > 14 days, and pre-treatment ambulatory status were significantly associated with both successful treatment and ambulatory status, affection of 1-2 vertebrae with successful treatment only. On univariable analyses, 1 × 8 and 5 × 4 Gy were not inferior to 5 × 5 Gy and longer-course regimens. Considering the three factors significant for both endpoints, three groups were designed (0, 1, 2-3 points) with treatment success rates of 4%, 15% and 39%, respectively (p < 0.0001), and post-treatment ambulatory rates of 4%, 43% and 86%, respectively (p < 0.0001).

CONCLUSION:

This score helps identify patients with MSCC who appear to benefit from palliative radiotherapy in terms of improved motor function or remaining ambulatory in spite of being near end of life.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Compresión de la Médula Espinal / Neoplasias de la Médula Espinal / Neoplasias de la Columna Vertebral Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Radiat Oncol Asunto de la revista: NEOPLASIAS / RADIOTERAPIA Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Asunto principal: Compresión de la Médula Espinal / Neoplasias de la Médula Espinal / Neoplasias de la Columna Vertebral Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Radiat Oncol Asunto de la revista: NEOPLASIAS / RADIOTERAPIA Año: 2022 Tipo del documento: Article País de afiliación: Alemania